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Outcome Disease N (BuCyE/
BEAM)
BuCyE vs. BEAMa
HR (95% CI)
p-value
Treatment
failure b, c
DLBCL 62/244 0.94 (0.57 e 1.57) 0.82
Other NHL 57/222 1.00 (0.62 e 1.63) 0.99
HL 64/253 2.08 (1.44 e 3.02) <.001
PRG b DLBCL 62/244 0.95 (0.55 e 1.63) 0.85
Other NHL 57/222 0.95 (0.59 e 1.54) 0.84
HL 64/253 2.19 (1.50 e 3.20) <.001
aBEAM is the reference b Adjusted for disease status at transplant c Inverse of
progression free survival.
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AutoHCT is the standard therapy for patients with lymphoma
who relapse after initial therapy because it improves pro-
gression free (PFS) and overall survival (OS). BEAM is the
most frequently utilized regimen but other regimens such as
those incorporating intravenous Bu are now being investi-
gated. This study compares outcomes from BuCyE in patients
enrolled in a phase II multicenter clinical trial from 2010 to
2012, to recipients of BEAM registered with the Center for
International Blood and Transplant Center (CIBMTR) from
2008 to 2011. After an interim analysis the clinical trial pro-
tocol was amended to enroll patients 65 y and younger due
to excess transplant related mortality (TRM) with BuCyE in
older patients. 184 recipients of BuCyE with lymphoma in
complete or partial response (PR) were matched to a
maximum of 4:1 with 729 controls based on age, perfor-
mance status, disease status prior to transplant and lym-
phoma histology. 177 cases had 4 matched controls and 97%
of controls had an age difference from controls of 5 years or
less. Median age is 50 years, 76% with performance status
greater than 90%, 35% with Hodgkin lymphoma (HL), 34%
diffuse large B-cell lymphoma (DLBCL), 16% mantle cell, 12%follicular and 3% other Non-Hodgkin Lymphoma (NHL) his-
tologies; 43% were in PR and median follow up was 22
months in both cohorts. Two-year cumulative incidences of
TRM were 3.3% (95% Conﬁdence Interval [CI] 1.4-6.6%) and
3.9% (95% CI, 2.4-5.7%), for BuCyE and BEAM, respectively.
Corresponding two-year probabilities of OS were 76% (95%
CI, 68-82%) and 78% (95% CI, 74-82%). Multivariate analysis
demonstrated a signiﬁcant interaction between disease and
conditioning regimen in evaluation of disease progression
(PRG) and treatment failure (1-PFS) outcomes (Table). Ana-
lyses by histology demonstrated that among patients with
DLBCL and other NHL histologies, there were no differences
in outcomes between conditioning groups. Among patients
with HL, the two-year cumulative incidence of PRG were 66%
(95% CI, 53-77%) and 38% (95% CI, 31-45%) and two-year PFS
were 33% (95% CI, 21-46%) and 59% (95% CI, 52-66%) for
BuCyE and BEAM, respectively with no difference in TRM or
OS. BuCyE were associated with comparable outcomes after
an autoHCT with BEAM conditioning among patients
younger than 65 years with NHL. In a subset of patients with
HL, BuCyE was associated with higher PRG and shorter PFS
compared to BEAM conditioning.233
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Introduction: High dose chemotherapy followed by Autol-
ogous Hematopoietic Stem Cell Transplantation (AHSCT) is
indicated for patients with Non-Hodgkin Lymphoma (NHL)
recurring after or resistant to primary therapy. Busulfan
based conditioning regimens are commonly used. Since the
approval of the intravenous formulation of busulfan inMarch
of 1999, AHSCT patients at UAB have been treated with a
regimen of pharmacokinetics directed (PK) busulfan
together with cyclophosphamide and etoposide (BuCyE). We
sought to evaluate the long term outcomes of this PK
directed dosing scheme.
Patients and Methods: Between April 1999 and November
2009, 69 consecutive patients with intermediate and high
risk NHL ranging in age from 19 to 74with amedian age of 54
*DLBC (n[40) *FL (n[15) *MCL (n[14)
Age at Transplant 55 (19-74) 55 (26-70) 57 (30-73)
Gender: Male 26 (65%) 10 (67%) 9 (64%)
Female 14 (35%) 5 (33%) 5 (36%)
Race: White 33 (83%) 12 (80%) 14 (100%)
Black 6 (15%) 2 (13%) 0
Other 1 (2%) 1 (7%) 0
Status at Transplant:
Complete Remission 1-3 13 (33%) 1 (7%) 6 (44%)
Partial Response 5 (12%) 1 (7%) 3 (21%)
Relapse 17 (43%) 6 (40%) 2 (14%)
Primary Refractory 5 (12%) 7 (46%) 3 (21%)
*DLBC: Diffuse Large B-Cell Lymphoma, FL: Follicular Lymphoma, MCL:
Mantle Cell Lymphoma
DLBC (n[40) FL (n[15) MCL (n[14)
100 day Mortality* 2 (5%) 2 (13%) 1 (7%)
100 day - 1 year Mortality 8 (20%) 4 (26%) 1 (7%)
3 year Overall Survival 63% 47% 57%
3 year Relapse-free Survival 60% 46% 50%
*Causes of 100 day Mortality Intracranial
hemorrhage
Disease
Heart
failure
Sepsis
Sepsis
Abstracts / Biol Blood Marrow Transplant 20 (2014) S151eS164 S163at the time of transplant were treatedwith a Bu “test dose” of
one 60 mg vial with adjustment of the remaining doses to
achieve an exposure of 20,000 uMol-min total Bu AUC fol-
lowed by Cy (2.5 g/m2) and E (1800 mg/m2).
Results: The average hospital stay was 25 days. There were 2
patient deaths prior to hospital discharge and 3 additional
deaths within the 100 day post-transplant period. At aminimum follow-up of 3 years the overall survival and dis-
ease free survival were 59% and 56%, respectively, for pa-
tients less than 54 years of age and 57% and 54%, respectively,
for patients more than 54 years of age. The 100 daymortality,
1 year mortality, overall survival and relapse-free survival
were similar in regardless of age (p value 0.5).
Conclusion: This PK directed BuCyE regimen followed by
AHSCT resulted in good overall and 3 year disease free sur-
vival in intermediate and high risk NHL patients. Survival
outcomes were similar regardless of patient age at the time
of transplant.
